Effect of zinc on standard pharmacotherapy hepatitis C treatment

Completed

• Conditions: hepatitis C patients; beta thalassemia major; Infection - Other infectious diseases; Blood - Haematological diseases

• Registration Number: ACTRN12613000897763
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-08-12
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

60 patients with recent diagnosis of chronic hepatitis C and previous diagnosis of beta thalassemia major

Exclusion Criteria

hepatitis B and human immunodeficiency viruses infected, recieving zinc or any complement containing zinc

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Sustained viral response (SVR) with PCR (Polymerase Chain Reaction) method<br>Definition of SVR:absence of detectable RNA of the hepatitis C virus in plasma for at least 6 months after discontinuing the treatment[after 48 weeks all medicine will be discontinue (standard pharmacotherapy with peg interferon plus ribavirin) and zinc/placebo. determination of SVR 6 months after withdrawal of medicines. ]

Secondary Outcome Measures

Name	Time	Method
none[none]